Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | PGK2 | P07205 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799008 | 0.85 | IDO1 (0.41) | PGK1PGK2RAPGEF4GRIN2BIDH1 | |
| SCHEMBL18643576 | 0.83 | TACR1 (0.44) | HSPA5TACR1RAPGEF4PDE2ATRPA1 | |
| SCHEMBL18266157 | 0.82 | TACR1 (0.35) | PGK1PGK2TACR1GRIN2BIDH1 | |
| SCHEMBL16703940 | 0.82 | GRIN2B (0.34) | HSPA5PGK1PGK2RAPGEF4GRIN2B | |
| SCHEMBL23328068 | 0.79 | PGK1 (0.48) | HSPA5PGK1PGK2RAPGEF4IDH1 | |
| SCHEMBL14547588 | 0.79 | PGK1 (0.43) | HSPA5PGK1PGK2RAPGEF4GRIN2B | |
| SCHEMBL14647825 | 0.79 | HSPA5 (0.32) | HSPA5TRPA1PDK2 | |
| SCHEMBL16129803 | 0.78 | SIGMAR1 (0.33) | HSPA5RAPGEF4PDE2A | |
| SCHEMBL14546887 | 0.76 | HSPA5 (0.37) | HSPA5PGK1PGK2TACR1RAPGEF4 | |
| SCHEMBL271754 | 0.74 | ALDH1A1 (0.42) | PGK1PGK2RAPGEF4IDH1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SSTR2, SSTR5, SSTR3 | HSPA5 1950/4885PGK1 3355/4885PGK2 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.